Pharma Equities Technical Momentum - Provectus Biopharma, Shire, Impax Labs, Zogenix, and TherapeuticsMD

LONDON, September 29, 2014 /PRNewswire/ --

On Friday, September 26, 2014, the NASDAQ Composite ended at 4,512.19, up 1.02%, the Dow Jones Industrial Average finished the day 0.99% higher at 17,113.15, and the S&P 500 closed at 1,982.85, up 0.86%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 745.73, up 0.30%, and the index has advanced 1.10% in the last one month. Investor-Edge has initiated coverage on the following equities: Provectus Biopharmaceuticals Inc. (NYSE MKT: PVCT), Shire PLC (NASDAQ: SHPG), Impax Laboratories Inc. (NASDAQ: IPXL), Zogenix Inc. (NASDAQ: ZGNX), and TherapeuticsMD Inc. (NYSE MKT: TXMD). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

On Friday, shares in Provectus Biopharmaceuticals Inc. recorded a trading volume of 0.34 million shares, lower than its three months average volume of 0.74 million shares. The stock finished the day at an intra-day low of $0.99, down 1.00%, and registered an intraday range of $0.99 and $1.03. Shares of Provectus Biopharmaceuticals Inc. have advanced 0.51% in the last one month and 13.55% in the past three months. However, the stock has plummeted 58.92% on YTD basis. Furthermore, the stock closed above its 50-day moving average. The stock's 200-day moving average of $1.67 is above its 50-day moving average of $0.96. Additionally, shares of the company have a Relative Strength Index (RSI) of 45.69. Sign up and read the free notes on PVCT at:

www.Investor-Edge.com/PVCT-29Sep2014

Shire PLC's stock gained 3.15%, to close Friday's session at $262.64, hitting a new 52-week high of $264.98. The stock recorded a trading volume of 2.56 million shares, above its three months average volume of 1.66 million shares. Over the last one month and past three months, Shire PLC's shares have surged 7.26% and 11.77%, respectively. Also, from the beginning of 2014, the stock has rallied 85.89%. The stock closed above its 50-day and 200-day moving averages. The stock's 50-day moving average of $248.99 is above its 200-day moving average of $188.22. Further, Shire PLC's stock has an RSI of 65.58. The complimentary notes on SHPG can be downloaded as in PDF format at:

www.Investor-Edge.com/SHPG-29Sep2014

On Friday, shares in Impax Laboratories Inc. finished the session 0.12% higher at $24.34. A total of 0.36 million shares were traded, which was below its three months average volume of 0.67 million shares. The stock moved between $23.88 and $24.52 during the session. Over the last one month and past three months, Impax Laboratories Inc.'s shares have declined 1.26% and 19.54%, respectively. Also, the stock has fallen by 3.18% since the start of this year. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $25.77 is greater than its 50-day moving average of $24.81. Shares of Impax Laboratories Inc. traded at a PE ratio of 27.31 and have an RSI of 46.52. Register for free on Investor-Edge and access the latest research on IPXL at:

www.Investor-Edge.com/IPXL-29Sep2014

Zogenix Inc.'s stock fluctuated between $1.16 and $1.20 before ending Friday's session up 0.85%, at $1.18. The stock reported a trading volume of 0.87 million shares, below its three months average volume of 1.98 million shares. Further, Zogenix Inc.'s shares have plummeted 7.81% over the last one month and 41.58% over the past three months. Also, the stock has lost 65.70% on YTD basis. The company's stock closed below its 50-day and 200-day moving averages. The stock's 200-day moving average of $2.62 is greater than its 50-day moving average of $1.32. Moreover, shares of Zogenix Inc. have an RSI of 41.17. The complete research on ZGNX is available for free at:

www.Investor-Edge.com/ZGNX-29Sep2014

TherapeuticsMD Inc.'s stock advanced 1.48%, to close Friday's session at $4.80, after vacillating between $4.67 and $5.20. The stock recorded a trading volume of 0.75 million shares, below its three months average volume of 2.11 million shares. Over the last one month and from the beginning of 2014, TherapeuticsMD Inc.'s shares have declined 13.67% and 7.87%, respectively. However, over the past three months, the stock has gained 1.05%. The company's stock closed below its 50-day and 200-day moving averages. The stock's 200-day moving average of $5.25 is above its 50-day moving average of $5.17. Further, TherapeuticsMD Inc.'s stock has an RSI of 39.58. Free in depth research on TXMD is available at:

www.Investor-Edge.com/TXMD-29Sep2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED